C-JWVPImmunis
stem cell-derived secretome, multi-active biologics, regenerative factors
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JWVP
C-JWVPC-JWVPstem cell-derived secretome, multi-active biologics, regenerative factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Immunis presents the view that age-acquired immune deficiency and age- or disease-related muscle atrophy are treatable conditions, and that stem cell-derived, natural-product immune therapies can be used to address age- and disease-related immune decline. The company frames its platform around secretomes and stem cell culture as the basis for these interventions.
SourceThe company presents aging as, in part, a loss or imbalance of beneficial secreted cellular factors that weakens immune regulation and contributes to age-related disease, especially muscle atrophy. Its stated belief is that stem cell-derived secretomes can replenish those missing signals, modulate immune responses, support tissue remodeling and regeneration, and therefore change the course of immune-related diseases and aging.
SourceImmunis states that age-acquired immune deficiency and age- or disease-related muscle atrophy can be targeted with stem cell-derived therapies. The company presents its STEM platform as an immune therapy based on secretomes and says its product uses stem cell culture to deliver natural, human immune modulators intended to address immune decline associated with aging and disease.
SourceImmunis states that age-driven immune deficits and age- or disease-related muscle atrophy can be addressed through secretome-based therapies. The company presents its investigational product, IMMUNA, as a natural human immune-modulating secretome intended to counter immune decline and improve healthspan, reflecting a belief that restoring age-impaired immune signaling can change outcomes in aging-related dysfunction.
Source